{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:03:17Z","timestamp":1793041397752,"version":"4.5.0"},"reference-count":78,"publisher":"Elsevier BV","issue":"20","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T00:00:00Z","timestamp":1648512000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.jacc.2022.03.353","type":"journal-article","created":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T15:52:33Z","timestamp":1652716353000},"page":"2058-2068","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":107,"title":["Sodium Glucose Cotransporter-2 Inhibition for Acute Myocardial Infarction"],"prefix":"10.1016","volume":"79","author":[{"given":"Jacob A.","family":"Udell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Schuyler","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"Petrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan D.","family":"Anker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1278-6245","authenticated-orcid":false,"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian F.","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2022.03.353_bib1","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2022.03.353_bib2","first-page":"234","volume":"3","author":"Desta","year":"2015","journal-title":"J\u00a0Am Coll Cardiol. HF"},{"key":"10.1016\/j.jacc.2022.03.353_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.amjcard.2018.03.005","article-title":"Myocardial Infarction Data Acquisition System Study Group. Risk factors and trends in incidence of heart failure following acute myocardial infarction","volume":"122","author":"Wellings","year":"2018","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2022.03.353_bib4","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.amjcard.2019.12.009","article-title":"Changing trends in the landscape of patients hospitalized with acute myocardial infarction (2001 to 2011) (from the Worcester Heart Attack Study)","volume":"125","author":"Mercado-Lubo","year":"2020","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2022.03.353_bib5","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1161\/CIRCULATIONAHA.120.047065","article-title":"Trends in recurrent coronary heart disease after myocardial infarction among US women and men between 2008 and 2017","volume":"143","author":"Peters","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2022.03.353_bib6","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1016\/j.ehj.2004.08.006","article-title":"An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry","volume":"25","author":"Velazquez","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2022.03.353_bib7","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1056\/NEJMoa043938","article-title":"Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both","volume":"352","author":"Solomon","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2022.03.353_bib8","first-page":"339","article-title":"Correlates and prognostic impact of new-onset heart failure after ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: insights from the INFUSE-AMI trial","volume":"7","author":"Giustino","year":"2018","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"10.1016\/j.jacc.2022.03.353_bib9","first-page":"179","article-title":"Post-myocardial infarction heart failure","volume":"6","author":"Bahit","year":"2018","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jacc.2022.03.353_bib10","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s10557-020-07027-4","article-title":"Established and emerging pharmacological therapies for post-myocardial infarction patients with heart failure: a review of the evidence","volume":"34","author":"De Luca","year":"2020","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jacc.2022.03.353_bib11","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.1938","article-title":"Twenty-year trends in outcomes for older adults with acute myocardial infarction in the United States","volume":"2","author":"Krumholz","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jacc.2022.03.353_bib12","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.118.004983","article-title":"Trends in performance and opportunities for improvement on a composite measure of acute myocardial infarction care","volume":"12","author":"Desai","year":"2019","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jacc.2022.03.353_bib13","unstructured":"Harrington JL, Jones WS, Udell JA, et al. Contemporary review of outcomes in patients with acute myocardial infarction and evidence of heart failure. J Am Coll Cardiol Heart Fail. In press."},{"key":"10.1016\/j.jacc.2022.03.353_bib14","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.ahj.2011.08.002","article-title":"Incidence and predictors of heart failure following percutaneous coronary intervention in ST-segment elevation myocardial infarction: the HORIZONS-AMI trial","volume":"162","author":"Kelly","year":"2011","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2022.03.353_bib15","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/S0735-1097(03)01057-X","article-title":"Predictors of late development of heart failure in stable survivors of myocardial infarction: the CARE study","volume":"42","author":"Lewis","year":"2003","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2022.03.353_bib16","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1001\/jamacardio.2016.0074","article-title":"Atherosclerotic burden and heart failure after myocardial infarction","volume":"1","author":"Gerber","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2022.03.353_bib17","doi-asserted-by":"crossref","first-page":"3667","DOI":"10.1161\/01.CIR.0000149806.01354.BF","article-title":"Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study","volume":"110","author":"Tokmakova","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2022.03.353_bib18","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJM200106213442501","article-title":"Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb\/IIIa inhibitor tirofiban","volume":"344","author":"Cannon","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2022.03.353_bib19","first-page":"390","article-title":"Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials","volume":"37","author":"Udell","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2022.03.353_bib20","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2022.03.353_bib21","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2022.03.353_bib22","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2022.03.353_bib23","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2022.03.353_bib24","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2022.03.353_bib25","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2022.03.353_bib26","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2022.03.353_bib27","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2022.03.353_bib28","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"16","key":"10.1016\/j.jacc.2022.03.353_bib29","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2022.03.353_bib30","first-page":"159","article-title":"CCS\/CHFS heart failure guidelines: clinical trial update on functional mitral regurgitation, SGLT2 inhibitors, ARNI in HFpEF, and tafamidis in amyloidosis","volume":"36","author":"O'Meara","year":"2020","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jacc.2022.03.353_bib31","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2020.06.019","article-title":"KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease","volume":"98","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacc.2022.03.353_bib32","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.jcjd.2020.08.001","article-title":"Pharmacologic glycemic management of type 2 diabetes in adults: 2020 update","volume":"44","author":"Lipscombe","year":"2020","journal-title":"Can J Diabetes"},{"key":"10.1016\/j.jacc.2022.03.353_bib33","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.jacc.2020.05.037","article-title":"2020 expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American College of Cardiology Solution Set Oversight Committee","volume":"76","author":"Das","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2022.03.353_bib34","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2022.03.353_bib35","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/ejhf.2026","article-title":"Heart\u00a0Failure Association of the European Society of Cardiology update on sodium-glucose co-transporter 2 inhibitors in heart failure","volume":"22","author":"Seferovic","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2022.03.353_bib36","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1002\/ejhf.1954","article-title":"Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart\u00a0Failure Association of the European Society of Cardiology","volume":"22","author":"Seferovic","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2022.03.353_bib37","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.2337\/dc21-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2021","volume":"44","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacc.2022.03.353_bib38","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1002\/ehf2.13148","article-title":"Early initiation of SGLT2 inhibitors is important, irrespective of ejection fraction: SOLOIST-WHF in perspective","volume":"7","author":"Verma","year":"2020","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jacc.2022.03.353_bib39","doi-asserted-by":"crossref","first-page":"251","DOI":"10.4070\/kcj.2020.0303","article-title":"Sodium\/glucose co-transporter 2 inhibitor, empagliflozin, alleviated transient expression of SGLT2 after myocardial infarction","volume":"51","author":"Lee","year":"2021","journal-title":"Korean Circ J"},{"key":"10.1016\/j.jacc.2022.03.353_bib40","doi-asserted-by":"crossref","first-page":"105788","DOI":"10.1016\/j.ejps.2021.105788","article-title":"Empagliflozin prevents from early cardiac injury post myocardial infarction in non-diabetic mice","author":"Liu","year":"2021","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.jacc.2022.03.353_bib41","first-page":"15","article-title":"SGLT2 inhibitor, canagliflozin, attenuates myocardial infarction in the diabetic and nondiabetic heart","volume":"4","author":"Lim","year":"2019","journal-title":"J\u00a0Am Coll Cardiol Basic Transl Sci"},{"key":"10.1016\/j.jacc.2022.03.353_bib42","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/j.jacc.2019.01.056","article-title":"Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics","volume":"73","author":"Santos-Gallego","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2022.03.353_bib43","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1161\/CIRCULATIONAHA.120.045691","article-title":"Empagliflozin in heart failure: diuretic and cardiorenal effects","volume":"142","author":"Griffin","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2022.03.353_bib44","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12933-020-01127-z","article-title":"Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial","volume":"19","author":"Shimizu","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacc.2022.03.353_bib45","first-page":"1232583","article-title":"Effects of newer antidiabetic drugs on endothelial function and arterial stiffness: a systematic review and meta-analysis","volume":"2018","author":"Batzias","year":"2018","journal-title":"J\u00a0Diabetes Res"},{"key":"10.1016\/j.jacc.2022.03.353_bib46","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1124\/jpet.118.253666","article-title":"Empagliflozin, an SGLT2 inhibitor, reduced the mortality rate after acute myocardial infarction with modification of cardiac metabolomes and antioxidants in diabetic rats","volume":"368","author":"Oshima","year":"2019","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.jacc.2022.03.353_bib47","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/ehf2.12336","article-title":"Empagliflozin reduces Ca\/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes","volume":"5","author":"Mustroph","year":"2018","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jacc.2022.03.353_bib48","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/ejhf.1473","article-title":"Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction","volume":"21","author":"Yurista","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2022.03.353_bib49","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s00125-017-4509-7","article-title":"Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na(+)\/H(+) exchanger, lowering of cytosolic Na(+) and vasodilation","volume":"61","author":"Uthman","year":"2018","journal-title":"Diabetologia"},{"key":"10.1016\/j.jacc.2022.03.353_bib50","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1093\/cvr\/cvz004","article-title":"Delayed ischaemic contracture onset by empagliflozin associates with NHE1 inhibition and is dependent on insulin in isolated mouse hearts","volume":"115","author":"Uthman","year":"2019","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacc.2022.03.353_bib51","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.cmet.2019.08.015","article-title":"SGLT2 inhibition with empagliflozin increases circulating provascular progenitor cells in people with type 2 diabetes mellitus","volume":"30","author":"Hess","year":"2019","journal-title":"Cell Metab"},{"key":"10.1016\/j.jacc.2022.03.353_bib52","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12933-019-0816-2","article-title":"SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart","volume":"18","author":"Li","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jacc.2022.03.353_bib53","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","article-title":"Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial","volume":"140","author":"Verma","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2022.03.353_bib54","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1161\/CIRCULATIONAHA.120.052186","article-title":"Effect of empagliflozin on left ventricular volumes in patients with type 2 diabetes, or prediabetes, and heart failure with reduced ejection fraction (SUGAR-DM-HF)","volume":"143","author":"Lee","year":"2021","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.jacc.2022.03.353_bib55","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1001\/jamacardio.2020.6827","article-title":"Associations of empagliflozin with left ventricular volumes, mass, and function in patients with heart failure and reduced ejection fraction: a substudy of the Empire HF randomized clinical trial","volume":"6","author":"Omar","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2022.03.353_bib56","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jacc.2020.11.008","article-title":"Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction","volume":"77","author":"Santos-Gallego","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2022.03.353_bib57","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","article-title":"SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control","volume":"17","author":"Cowie","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacc.2022.03.353_bib58","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1089\/dia.2019.0212","article-title":"Canagliflozin improves erythropoiesis in diabetes patients with anemia of chronic kidney disease","volume":"21","author":"Maruyama","year":"2019","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.jacc.2022.03.353_bib59","doi-asserted-by":"crossref","first-page":"7238","DOI":"10.1038\/s41598-020-64380-y","article-title":"Empagliflozin attenuates acute kidney injury after myocardial infarction in diabetic rats","volume":"10","author":"Kuno","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.jacc.2022.03.353_bib60","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1161\/CIRCULATIONAHA.119.044235","article-title":"Effect of empagliflozin on erythropoietin levels, iron stores, and red blood cell morphology in patients with type 2 diabetes mellitus and coronary artery disease","volume":"141","author":"Mazer","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2022.03.353_bib61","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jacc.2019.11.031","article-title":"Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review","volume":"75","author":"Zelniker","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2022.03.353_bib62","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S2213-8587(20)30382-X","article-title":"Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial","volume":"9","author":"Jensen","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacc.2022.03.353_bib63","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa2104508","article-title":"Angiotensin receptor-neprilysin inhibition in acute myocardial infarction","volume":"385","author":"Pfeffer","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2022.03.353_bib64","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2022.03.353_bib65","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ahj.2020.07.014","article-title":"Timing of randomization after an acute coronary syndrome in patients with type 2 diabetes mellitus","volume":"229","author":"Elharram","year":"2020","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2022.03.353_bib66","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1161\/CIRCULATIONAHA.119.039996","article-title":"Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes mellitus and previous myocardial infarction","volume":"139","author":"Furtado","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2022.03.353_bib67","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1161\/CIRCULATIONAHA.116.024764","article-title":"Use of sodium glucose cotransporter 2 inhibitors in the hands of cardiologists: with great power comes great responsibility","volume":"134","author":"Cherney","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2022.03.353_bib68","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/ejhf.1713","article-title":"Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF)","volume":"22","author":"Damman","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"10.1016\/j.jacc.2022.03.353_bib69","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.007048","article-title":"Effect of empagliflozin as an add-on therapy on decongestion and renal function in patients with diabetes hospitalized for acute decompensated heart failure: a prospective randomized controlled study","volume":"14","author":"Tamaki","year":"2021","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2022.03.353_bib70","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jacc.2021.01.020","article-title":"SGLT2 inhibitors","volume":"77","author":"Cheng","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"14","key":"10.1016\/j.jacc.2022.03.353_bib71","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","volume":"42","author":"Collet","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2022.03.353_bib72","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.jacc.2022.03.353_bib73","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.jacc.2015.10.005","volume":"67","author":"Levine","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"24","key":"10.1016\/j.jacc.2022.03.353_bib74","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","article-title":"2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"64","author":"Amsterdam","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jacc.2022.03.353_bib75","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1001\/jamainternmed.2019.3884","article-title":"Trends in aggregate use and associated expenditures of antihyperglycemic therapies among US Medicare beneficiaries between 2012 and 2017","volume":"180","author":"Sumarsono","year":"2020","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jacc.2022.03.353_bib76","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1016\/j.jacc.2018.08.2202","article-title":"Prescriber patterns of SGLT2i after expansions of U.S. Food and Drug administration labeling","volume":"72","author":"Vaduganathan","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2022.03.353_bib77","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1001\/jama.2019.1122","article-title":"Levels of evidence supporting American College of Cardiology\/American Heart Association and European Society of Cardiology Guidelines, 2008-2018","volume":"321","author":"Fanaroff","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2022.03.353_bib79","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ahj.2019.12.004","article-title":"Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction-The EMMY trial (NCT03087773)","volume":"221","author":"Tripolt","year":"2020","journal-title":"Am Heart J"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109722045661?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109722045661?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:48:51Z","timestamp":1760017731000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109722045661"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":78,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0735109722045661"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2022.03.353","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sodium Glucose Cotransporter-2 Inhibition for Acute Myocardial Infarction","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2022.03.353","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}